AIM ImmunoTech Total Assets 2010-2025 | AIM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AIM ImmunoTech total assets from 2010 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AIM ImmunoTech total assets from 2010 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$80.2B
Zoetis (ZTS)	$68.3B
Daiichi Sankyo, - (DSNKY)	$47.1B
Takeda Pharmaceutical (TAK)	$46.9B
BeOne Medicines - (ONC)	$32.3B
Sandoz Group AG (SDZNY)	$26.4B
Summit Therapeutics (SMMT)	$20.8B
Merck (MKKGY)	$17.3B
Shionogi (SGIOY)	$14.5B
United Therapeutics (UTHR)	$13.8B
Neurocrine Biosciences (NBIX)	$13.2B
Orion OYJ (ORINY)	$11.7B
IPSEN (IPSEY)	$10.9B
Stevanato Group S.p.A (STVN)	$7.7B
Corcept Therapeutics (CORT)	$7.3B
Madrigal Pharmaceuticals (MDGL)	$6.8B
Grifols, S.A (GRFS)	$6.8B
Ionis Pharmaceuticals (IONS)	$6.7B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.4B
Hypermarcas (HYPMY)	$3.1B
Crinetics Pharmaceuticals (CRNX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.6B
Procaps Group, S.A (PROCF)	$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.1B
Ocular Therapeutix (OCUL)	$1.9B
BioCryst Pharmaceuticals (BCRX)	$1.8B